Exposure-Response Analyses of Various Efficacy and Safety Endpoints in Support of Registrational Dose Selection of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma

被引：0
|
作者：
Milberg, Oleg [1 ]
Chiu, Joannellyn [1 ]
Hazra, Anasuya [1 ]
Upadhyay, Sameer [1 ]
Kroog, Glenn S. [1 ]
Lorenc, Karen Rodriguez [1 ]
Davis, John D. [1 ]
Dicioccio, A. Thomas [1 ]
Harnisch, Lutz O. [1 ]
Chittenden, Jason [1 ]
机构：
[1] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-200109
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7056 / 7057
页数：2
相关论文
共 50 条
  • [21] Pharmacokinetics and Exposure-Response Analyses to Support Dose Selection of Upadacitinib in Crohn's Disease
    Bhatnagar, Sumit
    Schlachter, Louisa
    Eckert, Doerthe
    Stodtmann, Sven
    Liu, Wei
    Lacerda, Ana P.
    Mohamed, Mohamed-Eslam F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (05) : 1240 - 1251
  • [22] EXPOSURE-SAFETY-EFFICACY ANALYSIS OF IXAZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DOSE SELECTION FOR PHASE III TRIAL OF IXAZOMIB MAINTENANCE THERAPY
    Gupta, N.
    Labotka, R.
    Liu, G.
    Venkatakrishnan, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S13 - S14
  • [23] Cabozantinib exposure-response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma
    Linh Nguyen
    Chapel, Sunny
    Tran, Benjamin Duy
    Lacy, Steven
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2019, 46 (06) : 577 - 589
  • [24] Exposure-response analysis of venetoclax in combination with carfilzomib and dexamethasone in t(11;14)-positive relapsed/refractory multiple myeloma patients
    Badawi, Mohamed
    Engelhardt, Benjamin
    Dobkowska, Edyta
    Deng, Rong
    Kaufman, Jonathan
    Menon, Rajeev
    Salem, Ahmed Hamed
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S161 - S162
  • [25] EXPOSURE-RESPONSE ANALYSES OF BARDOXOLONE METHYL SAFETY AND EFFICACY AND CLINICAL TRIAL SIMULATIONS TO INFORM PHASE III DOSE SELECTION
    Klein, Cheri
    Noertersheuser, Peter
    Mensing, Sven
    Teuscher, Nathan
    Meyer, Colin
    Dumas, Emily
    Awni, Walid
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 403 - 403
  • [26] Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma
    Squifflet, Pierre
    Michiels, Stefan
    Siegel, David
    Vij, Ravi
    Jagannath, Sundar
    Saad, Everardo D.
    Rajangam, Kanya
    Ro, Sunhee Kwon
    Buyse, Marc
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (11): : 680 - 686
  • [27] Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma
    Lacy, Steven
    Nielsen, Jace
    Yang, Bei
    Miles, Dale
    Linh Nguyen
    Hutmacher, Matt
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (06) : 1061 - 1070
  • [28] Exposure-Response Analysis Supports a Lower Dose of Venetoclax in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Patients When Combined with Daratumumab and Dexamethasone
    Badawi, Mohamed A.
    Engelhardt, Benjamin
    Badillo, Jesus
    Suleiman, Ahmed Abbas
    Fleming, Leanne Lash
    Luo, Yan
    Kaufman, Jonathan L.
    Bahlis, Nizar Jacques
    Menon, Rajeev
    Salem, Ahmed Hamed
    BLOOD, 2022, 140 : 10122 - 10123
  • [29] Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis
    Al-Badriyeh, Daoud
    Shafei, Laila
    Bashir, Shaima
    Abushanab, Dina
    Hamad, Anas
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 263 - 263
  • [30] Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
    Xiaohui Gao
    Hui Zeng
    Xiaoyan Zhao
    Haibing Wu
    Minchao Yan
    Yuan Li
    Gang Zhang
    Fei Sun
    BMC Cancer, 23
12345